WuXi Biologics reports strong 2024, projects growth in 2025

WuXi Biologics announced its 2024 annual results, showcasing a resilient performance and positive outlook. Group revenue increased by 9.6% year-over-year to CNY 18.7 billion, while non-COVID revenue surged by 13.1%. Adjusted net profit saw a 9.0% increase, and adjusted EBITDA climbed 14.4% year-over-year. The company secured 151 new projects during the year and is focused on maximizing its CRDMO model.